Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) posted a decline in its consolidated net profit to 21.5 billion Indian rupees in the fiscal fourth quarter ended March 31, against 26.5 billion rupees a year ago.
Earnings per share contracted to 9.0 rupees compared with the year-ago figure of 11.1 rupees, according to a Thursday filing to the Indian stock exchanges by the pharmaceutical company.
Revenue from operations in fiscal Q4, however, increased to 129.6 billion rupees from 119.8 billion rupees a year earlier.
The company's board declared a final dividend of 5.50 rupees per equity share of 1 rupee each.
Sun Pharma's shares were down nearly 3% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。